Cannabis Strains Available in UK Pharmacies — Complete List

Profile

THC: 13.5% | CBD: <0.5%

Bedrobinol is a predominantly THC-rich strain designed for patients requiring significant analgesic and anti-inflammatory effects. The strain combines cannabinoid potency with relatively low CBD content, making it suitable for patients with chronic pain conditions who do not require balanced THC/CBD ratios.

Therapeutic Uses

• Chronic pain management
• Neuropathic pain
• Multiple sclerosis spasticity
• Cancer-related symptoms

Clinical Notes

Bedrobinol is typically prescribed to established medical cannabis users or those with specific clinical indications requiring higher THC levels. Patients must demonstrate adequate tolerance to THC before initiation.

Profile

THC: 22% | CBD: <1%

Bedrocan represents the highest-THC strain available through UK pharmacies, providing maximum cannabinoid potency for patients with severe symptoms. The strain has been extensively researched in clinical settings and features prominently in pain management protocols.

Therapeutic Applications

• Severe chronic pain
• Intractable spasticity
• Treatment-resistant nausea
• Severe anxiety with pain components

Access Considerations

Due to its high potency, Bedrocan typically requires prior clinical assessment and titration with lower-strength products. Specialist clinicians generally recommend this strain only after failed conventional treatments and demonstrated THC tolerance.

Profile

THC: 6.5% | CBD: 8%

Bediol offers a balanced THC/CBD profile, making it an excellent choice for patients seeking the combined therapeutic benefits of both cannabinoids. The relatively equal ratio supports both pain relief and anti-anxiety effects whilst maintaining a lower overall cannabinoid burden.

Ideal Patient Profile

• First-time medical cannabis users
• Patients with anxiety and pain components
• Those requiring daytime use
• Elderly patients or those with THC sensitivity

Typical Dosing Approach

Bediol’s balanced ratio allows for flexible dosing schedules. Many patients begin with this strain before titrating to either higher-THC or higher-CBD alternatives based on clinical response.

Profile

THC: <1% | CBD: 9%

Bedrolite is the CBD-dominant strain in the Bedrocan range, providing therapeutic cannabinoid benefits with minimal psychoactive effects. This strain suits patients requiring symptom relief without THC-related side effects or those subject to employment drug screening.

Clinical Indications

• Childhood epilepsy syndromes
• Anxiety disorders
• Inflammatory conditions
• Patients requiring THC avoidance

Advantages

Bedrolite provides a non-intoxicating option for patients who may be sensitive to THC or require ongoing work capability. The high CBD content offers neuroprotective and anxiolytic properties supported by emerging clinical evidence.

Overview

THC: 20% | CBD: 4%

T20/C4 represents a moderately high-THC strain with supplementary CBD content. Manufactured to pharmaceutical standards, this product provides a more potent option than balanced strains whilst retaining some CBD for synergistic effects.

Distinctive Features

• Consistent cannabinoid ratios across batches
• Standardised particle size for uniform dosing
• Rigorous contamination testing
• Detailed laboratory analysis accompanying each prescription

Patient Suitability

T20/C4 suits patients demonstrating moderate THC tolerance and requiring enhanced therapeutic effects beyond balanced formulations. The CBD component moderates some THC-related side effects whilst the higher THC supports symptom relief.

Cost Considerations

T20/C4 typically costs between £5 and £10 per gram through private clinics, with pricing varying by pharmacy and supplier relationships. NHS availability remains limited to specific clinical pathways.

Key Products

• Tweed products: Range from balanced to THC-dominant formulations
• High-CBD options: For patients avoiding THC
• Standardised ratios: Ensuring dose precision and consistency

Quality Assurance

Spectrum Therapeutics implements comprehensive testing for microbial contamination, heavy metals, pesticide residues, and cannabinoid potency. Each batch includes detailed laboratory certificates of analysis.

Cost Profile

Spectrum products typically range from £4 to £12 per gram depending on cannabinoid content and specific formulation, with private prescriptions required for most UK patients.